Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Oncology Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CCR6 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery | CCR6 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. High titer, sequence verified. |
View CCR6 Products |
| Antigen | CCR6 Extracellular Loops Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. |
View CCR6 Products |
| Benchmark Ab | Anti-CCR6 Recombinant Antibody Sequence-derived positive control for binding and neutralization assays. |
View CCR6 Products |
| Validator | CCR6 siRNA Set For knockdown verification in functional assays. |
View CCR6 Products |
| Related Target A | CCL20 (LARC) The primary chemokine ligand for CCR6; essential for ligand-competition and chemotaxis assays. |
View CCL20 Products |
| Related Target B | IL17A Downstream effector cytokine of the Th17 pathway driven by CCR6+ cell homing. |
View IL17A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Native Conformation Maintenance | Lentiviral transduction for stable cell line expression, preserving native 7-transmembrane structure. |
| Subfamily Counter-Screening (CCR1-10) | Sequence-verified homologous chemokine receptor lentiviruses for specificity profiling. |
| Lack of Controls | Recombinant sequence-derived benchmark antibodies included |
| False Positives | Validated siRNA included for target-specific knockdown verification |
Live CCR6/CD196 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CCR6 therapeutics is intensifying, with major players shifting focus from traditional small-molecule antagonists to highly selective monoclonal antibodies and bispecifics. As first-generation therapies reach the clinic, the next wave of R&D is targeting the Th17/Treg axis to address autoimmune diseases like psoriasis and inflammatory bowel disease (IBD), alongside novel applications in colorectal cancer microenvironment modulation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | GSK, AstraZeneca | Psoriasis, Inflammatory Bowel Disease | Chemotaxis inhibition assay (Requires high-titer Lentivirus for stable cell lines) |
| Bispecific Antibody | Innovent, Amgen | Autoimmune Diseases | Dual-targeting validation (Requires sequence-verified CCL20 and target antigens) |
| Small Molecule | ChemoCentryx, Pfizer | Rheumatoid Arthritis, IBD | Calcium flux / IP-One assay (Requires stable receptor-expressing host cell lines) |